Shopping Cart
- Remove All
Your shopping cart is currently empty
SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $30 | In Stock | |
| 5 mg | $64 | In Stock | |
| 10 mg | $113 | In Stock | |
| 25 mg | $239 | In Stock | |
| 50 mg | $389 | In Stock | |
| 100 mg | $582 | In Stock | |
| 200 mg | $828 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $45 | In Stock |
| Description | SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease. |
| Molecular Weight | 329.48 |
| Formula | C20H31N3O |
| Cas No. | 1629138-41-5 |
| Smiles | O=C(NC1CCCCC1)N(CC1CCNCC1)Cc1ccccc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (166.93 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.07 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.